Analysis

Mid-day market update: Stocks extend losses, Dow tumbles over 400 points

U.S. stocks extended its earlier losses midway through trading on Tuesday, amid rising tensions between Russia and Ukraine. Russian President Vladimir Putin said he would recognize the independence of two Russian-led breakaway regions of Ukraine and ordered Russian troops to go into eastern Ukraine.

The Dow traded down 1.31% to 33,631.65 while the NASDAQ fell 1.42% to 13,356.05. The S&P also fell, dropping, 1.08% to 4,301.81.

Leading and Lagging Sectors

Utilities shares slipped by just 0.1% on Tuesday. Meanwhile, top gainers in the sector included Empresa Distribuidora y Comercializadora Norte Sociedad Anónima EDN +6.73% (Get Free Alerts for EDN), up 7% and Companhia de Saneamento Básico do Estado de São Paulo - SABESP SBS +6.35% up 7%.

In trading on Tuesday, consumer discretionary shares tumbled by 3.3%.

Top Headline

Home Depot Inc HD -9.55% reported better-than-expected earnings for its fourth quarter and raised its dividend.

Home Depot reported fourth-quarter FY21 sales growth of 10.7% year-on-year, to $35.72 billion, beating the analyst consensus of $34.87 billion. EPS of $3.21 beat the analyst consensus of $3.17.

Home Depot raised the quarterly dividend by 15% to $1.90 from $1.65 per share, payable on March 24, 2022, to shareholders of record on the close of business on March 10, 2022.

The company expects FY22 EPS growth to be in the low single digits. Home Depot sees FY22 sales and comparable sales growth to be slightly positive.

Equities Trading UP

Meritor, Inc. MTOR +44.95% shares shot up 45% to $35.81. Cummins Inc CMI -1.69% agreed to acquire electric powertrain solutions provider Meritor for about $3.7 billion, including assumed debt and net of acquired cash.

Shares of Indonesia Energy Corporation Limited INDO +64.37% got a boost, shooting 58% to $7.09.

Ocugen, Inc. OCGN +24.27% shares were also up, gaining 29% to $4.46 after the company announced the FDA lifted its clinical hold on the company's COVID-19 vaccine study in the US.

Equities Trading DOWN

Allarity Therapeutics, Inc. ALLR -31.03% shares tumbled 31% to $4.5750. The FDA provided Allarity Therapeutics with a Refusal to File (RTF) letter for a marketing application for dovitinib for the third-line treatment of metastatic renal cell carcinoma (mRCC).

Shares of Dogness (International) Corporation DOGZ -40.98% were down 40% to $2.55 after the company reported entry into agreement for registered direct offering of approximately $5.66 million of class A common shares.

Homology Medicines, Inc. FIXX -31.22% was down, falling 31% to $2.6601. The FDA placed a clinical hold on Homology Medicines’ pheNIX gene therapy trial of HMI-102 from the FDA. An official clinical hold letter is expected within 30 days.

Commodities

In commodity news, oil traded up 2.1% to $93.00, while gold traded up 0.3% to $1,905.10.

Silver traded up 1.2% Tuesday to $24.275 while copper fell 0.1% to $4.5085.

Euro zone

European shares were mixed today. The eurozone’s STOXX 600 gained 0.07%, London’s FTSE 100 rose 0.13%, while Spain’s IBEX 35 Index rose 0.05%. The German DAX fell 0.26%, French CAC 40 slipped 0.01% and Italy’s FTSE MIB Index fell 0.02%.

The UK government reported a £2.9 billion surplus in its public finances in January, versus a £2.5 billion deficit a year ago. The Ifo Business Climate indicator for Germany climbed to 98.9 in February from a revised level of 96 in January. The annual inflation rate in Italy increased to 4.8% in January from 3.9% in the earlier month.

Economics

The S&P CoreLogic Case-Shiller home price index surged 18.6% year-over-year in December.

The FHFA House Price Index rose 1.2% from a month ago in December.

The IHS Markit manufacturing PMI rose to 57.5 in February from 55.5 in the previous month, while services PMI climbed to 56.7 from 51.2.

The Conference Board’s consumer confidence index fell to 110.5 in February from previous reading of 111.1.

Federal Reserve Bank of Atlanta President Raphael Bostic is set to speak at 3:30 p.m. ET.

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.


RELATED CONTENT

Loading ...



Copyright © 2024 FOREXSTREET S.L., All rights reserved.